Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.34 |
| ▸ | TK2 | O00142 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14785922 | 0.87 | PYGM (0.35) | PYGMTK2LMNASMN1; SMN2 | |
| SCHEMBL27355175 | 0.84 | TK1 (0.40) | TK2LMNATK1 | |
| SCHEMBL3968330 | 0.81 | PYGM (0.37) | PYGMTK2LMNASMN1; SMN2TK1 | |
| SCHEMBL3973110 | 0.81 | PYGM (0.37) | PYGMTK2LMNASMN1; SMN2TK1 | |
| SCHEMBL3978670 | 0.81 | PYGM (0.37) | PYGMTK2LMNASMN1; SMN2TK1 | |
| SCHEMBL3079836 | 0.80 | TK2 (0.52) | TK2TK1 | |
| SCHEMBL3968348 | 0.80 | PYGM (0.35) | PYGMTK2LMNASMN1; SMN2TK1 | |
| SCHEMBL8930585 | 0.76 | SLC28A1 (0.45) | — | |
| SCHEMBL7256295 | 0.74 | TK1 (0.39) | TK2LMNATK1 | |
| SCHEMBL3977864 | 0.74 | RNASE1 (0.35) | PYGMTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | PYGM 1888/4885TK2 34/4885LMNA 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.